864 related articles for article (PubMed ID: 25477054)
1. Long-term follow-up of patients who received repeat-dose rituximab as maintenance therapy for ANCA-associated vasculitis.
Alberici F; Smith RM; Jones RB; Roberts DM; Willcocks LC; Chaudhry A; Smith KG; Jayne DR
Rheumatology (Oxford); 2015 Jul; 54(7):1153-60. PubMed ID: 25477054
[TBL] [Abstract][Full Text] [Related]
2. Rituximab for induction and maintenance treatment of ANCA-associated vasculitides: a multicentre retrospective study on 80 patients.
Charles P; Néel A; Tieulié N; Hot A; Pugnet G; Decaux O; Marie I; Khellaf M; Kahn JE; Karras A; Ziza JM; Deligny C; Tchérakian C; Guillevin L;
Rheumatology (Oxford); 2014 Mar; 53(3):532-9. PubMed ID: 24282319
[TBL] [Abstract][Full Text] [Related]
3. Rituximab for remission maintenance in relapsing antineutrophil cytoplasmic antibody-associated vasculitis.
Smith RM; Jones RB; Guerry MJ; Laurino S; Catapano F; Chaudhry A; Smith KG; Jayne DR
Arthritis Rheum; 2012 Nov; 64(11):3760-9. PubMed ID: 22729997
[TBL] [Abstract][Full Text] [Related]
4. Long-term efficacy and safety of pre-emptive maintenance therapy with rituximab in granulomatosis with polyangiitis: results from a single centre.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2013 Nov; 52(11):2041-7. PubMed ID: 23934313
[TBL] [Abstract][Full Text] [Related]
5. Rituximab for remission induction in elderly patients with ANCA-associated vasculitis.
Timlin H; Lee SM; Manno RL; Seo P; Geetha D
Semin Arthritis Rheum; 2015 Aug; 45(1):67-9. PubMed ID: 25796088
[TBL] [Abstract][Full Text] [Related]
6. Rituximab for induction and maintenance therapy in granulomatosis with polyangiitis (Wegener's). Results of a single-center cohort study on 66 patients.
Calich AL; Puéchal X; Pugnet G; London J; Terrier B; Charles P; Mouthon L; Guillevin L;
J Autoimmun; 2014 May; 50():135-41. PubMed ID: 24703438
[TBL] [Abstract][Full Text] [Related]
7. Long-term efficacy of remission-maintenance regimens for ANCA-associated vasculitides.
Terrier B; Pagnoux C; Perrodeau É; Karras A; Khouatra C; Aumaître O; Cohen P; Decaux O; Desmurs-Clavel H; Maurier F; Gobert P; Quémeneur T; Blanchard-Delaunay C; Bonnotte B; Carron PL; Daugas E; Ducret M; Godmer P; Hamidou M; Lidove O; Limal N; Puéchal X; Mouthon L; Ravaud P; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1150-1156. PubMed ID: 29724729
[TBL] [Abstract][Full Text] [Related]
8. Rituximab for remission induction and maintenance in refractory granulomatosis with polyangiitis (Wegener's): ten-year experience at a single center.
Cartin-Ceba R; Golbin JM; Keogh KA; Peikert T; Sánchez-Menéndez M; Ytterberg SR; Fervenza FC; Specks U
Arthritis Rheum; 2012 Nov; 64(11):3770-8. PubMed ID: 22730028
[TBL] [Abstract][Full Text] [Related]
9. Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models.
McClure ME; Zhu Y; Smith RM; Gopaluni S; Tieu J; Pope T; Kristensen KE; Jayne DRW; Barrett J; Jones RB
Rheumatology (Oxford); 2021 Mar; 60(3):1491-1501. PubMed ID: 33141217
[TBL] [Abstract][Full Text] [Related]
10. Rituximab in the treatment of refractory or relapsing eosinophilic granulomatosis with polyangiitis (Churg-Strauss syndrome).
Thiel J; Hässler F; Salzer U; Voll RE; Venhoff N
Arthritis Res Ther; 2013 Sep; 15(5):R133. PubMed ID: 24286362
[TBL] [Abstract][Full Text] [Related]
11. Impact of rituximab trials on the treatment of ANCA-associated vasculitis.
Alberici F; Jayne DR
Nephrol Dial Transplant; 2014 Jun; 29(6):1151-9. PubMed ID: 24126571
[TBL] [Abstract][Full Text] [Related]
12. Single-dose rituximab for remission induction and maintenance therapy in ANCA-associated vasculitis: a retrospective analysis of 17 patients.
Moog P; Probst M; Kuechle C; Hauser C; Heemann U; Thuermel K
Scand J Rheumatol; 2014; 43(6):519-23. PubMed ID: 25179776
[TBL] [Abstract][Full Text] [Related]
13. Is B-cell depletion first choice in antineutrophil cytoplasmic antibody-associated vasculitis?
Kallenberg CG
Curr Opin Rheumatol; 2014 May; 26(3):292-8. PubMed ID: 24646946
[TBL] [Abstract][Full Text] [Related]
14. Comparison of individually tailored versus fixed-schedule rituximab regimen to maintain ANCA-associated vasculitis remission: results of a multicentre, randomised controlled, phase III trial (MAINRITSAN2).
Charles P; Terrier B; Perrodeau É; Cohen P; Faguer S; Huart A; Hamidou M; Agard C; Bonnotte B; Samson M; Karras A; Jourde-Chiche N; Lifermann F; Gobert P; Hanrotel-Saliou C; Godmer P; Martin-Silva N; Pugnet G; Matignon M; Aumaitre O; Viallard JF; Maurier F; Meaux-Ruault N; Rivière S; Sibilia J; Puéchal X; Ravaud P; Mouthon L; Guillevin L;
Ann Rheum Dis; 2018 Aug; 77(8):1143-1149. PubMed ID: 29695500
[TBL] [Abstract][Full Text] [Related]
15. B cell repopulation kinetics after rituximab treatment in ANCA-associated vasculitides compared to rheumatoid arthritis, and connective tissue diseases: a longitudinal observational study on 120 patients.
Thiel J; Rizzi M; Engesser M; Dufner AK; Troilo A; Lorenzetti R; Voll RE; Venhoff N
Arthritis Res Ther; 2017 May; 19(1):101. PubMed ID: 28521808
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of rituximab treatment in patients with antineutrophil cytoplasmic antibody-associated vasculitides: results from a German registry (GRAID).
Roll P; Ostermeier E; Haubitz M; Lovric S; Unger L; Holle J; Kötter I; Henes JC; Bergner R; Rubbert-Roth A; Specker C; Schulze-Koops H; Müller-Ladner U; Fleck M; Burmester GR; Hiepe F; Heitmann S; Aringer M; Fischer-Betz R; Dörner T; Tony HP
J Rheumatol; 2012 Nov; 39(11):2153-6. PubMed ID: 22984269
[TBL] [Abstract][Full Text] [Related]
17. Serum immunoglobulin levels and risk factors for hypogammaglobulinaemia during long-term maintenance therapy with rituximab in patients with granulomatosis with polyangiitis.
Besada E; Koldingsnes W; Nossent JC
Rheumatology (Oxford); 2014 Oct; 53(10):1818-24. PubMed ID: 24831059
[TBL] [Abstract][Full Text] [Related]
18. Rituximab versus cyclophosphamide for ANCA-associated vasculitis with renal involvement.
Geetha D; Specks U; Stone JH; Merkel PA; Seo P; Spiera R; Langford CA; Hoffman GS; Kallenberg CG; St Clair EW; Fessler BJ; Ding L; Tchao NK; Ikle D; Jepson B; Brunetta P; Fervenza FC;
J Am Soc Nephrol; 2015 Apr; 26(4):976-85. PubMed ID: 25381429
[TBL] [Abstract][Full Text] [Related]
19. The "4 plus 2" rituximab protocol makes maintenance treatment unneeded in patients with refractory ANCA-associated vasculitis: A 10 years observation study.
Roccatello D; Sciascia S; Rossi D; Alpa M; Naretto C; Radin M; Fenoglio R; Baldovino S; Menegatti E
Oncotarget; 2017 Aug; 8(32):52072-52077. PubMed ID: 28881714
[TBL] [Abstract][Full Text] [Related]
20. Rituximab use in patients with ANCA-associated vasculitis: clinical efficacy and impact on immunological parameters.
Chocova Z; Hruskova Z; Mareckova H; Svobodova B; Duskova D; Bednarova V; Jancova E; Rysava R; Tesar V
Clin Rheumatol; 2015 Jan; 34(1):107-15. PubMed ID: 25388644
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
